Kingdomway(SZ:002626)2022-12-03 09:52Group 1: Company Performance and Strategy - The company aims for better performance in 2018, building on a relatively positive 2017 [1] - The health supplement market in China is still in the education phase, indicating significant future growth potential [2] - The company plans to enhance its brand presence and marketing efforts to capture opportunities in the health industry, projected to reach 8 trillion yuan by 2020 [2] Group 2: Product Development and Market Trends - The company has seen high sales growth in coenzyme Q10, with expectations for continued price improvement [3] - The health supplement business is identified as a key profit growth area for the year, focusing on coenzyme Q10 and sports nutrition products [3] - The company is not currently involved in cosmetics, despite inquiries about potential collaborations [3] Group 3: Financial and Operational Insights - The company reported a 5.6% increase in R&D expenses compared to the previous year, aimed at enhancing core competitiveness through innovation [6] - There are no immediate impacts from rising coal prices or U.S.-China trade tensions on the company's operations [4] - The company has a robust cash flow and is considering further expansion in coenzyme and vitamin production [5] Group 4: Investor Relations and Communication - The company encourages investor engagement and is open to discussions, although site visits are currently not available [6] - The management expresses gratitude for investor confidence and commits to enhancing overall competitiveness to reward shareholders [4]